In 2021, under the guidance of the China Association for Science and Technology (CAST), the Science and Technology Communication Center of CAST and the Shenzhen Association for Science and Technology (SZAST) initiated the selection of the first “Science and Innovation in China” Youth Entrepreneurship List—Shenzhen U30 Youth Innovation and Entrepreneurship Activity. This initiative focuses on high-tech fields such as artificial intelligence, chip design, biomedicine, big data, advanced manufacturing, energy-saving and environmental protection, and new materials, among others.

In 2022, following the Shenzhen U30 selection work program, 30 outstanding young technology entrepreneurs were ultimately chosen. The selection process involved recommendations from various community sectors, preliminary project assessments, expert evaluations, and the collection of opinions. Dr. Anjin Xianyu, co-founder and CTO of META Pharmaceuticals, was honored to be included in this prestigious list.

Dr. Anjin Xianyu, a co-founder and CTO of META Pharmaceuticals, plays a pivotal role in the company’s growth. His responsibilities span the development of META’s proprietary AI-assisted metabolism and pathway drug target discovery platform. By synergizing artificial intelligence with experimental biology, Dr. Xianyu drives innovation in the field. His expertise lies in creating computational models for metabolic targets, ensuring that META remains at the forefront of cutting-edge science and technology.

“Shenzhen U30 Young Entrepreneurs in “Science and Innovation China

In no particular order

META Pharmaceuticals is the first commercialization company in China to deeply cultivate in the emerging field of immune metabolism, with a focus on developing first-in-class original drugs. The founding team primarily hails from top research hospitals in the U.S., including Cornell University Medical College and Memorial Sloan Kettering Cancer Center in New York City. In June of 2022, META Pharmaceuticals successfully completed its Seed and Pre-A rounds of financing, totaling hundreds of millions of RMB. This significant milestone was led by Forcefield Ventures, XtalPi Inc., IMO Ventures, and Tiantu Capital.